Eisai Gives Full Aduhelm Responsibility To Biogen Under Amended Agreement
Japanese Pharma Trades 50-50 Deal For Single-Digit Royalty
The companies amended the terms of their Alzheimer’s collaboration to give Biogen full decision-making control over Aduhelm immediately. Eisai’s 50% share of profits and losses from the drug switches to a 2% royalty in 2023. The partners’ agreement for Eisai-led lecanemab remains intact.
